奥利司他所致草酸盐肾病：慢性肾脏病一个未得到充分认识的病因。
Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.
作者信息
Solomon Laurence Richard, Nixon Andrew Christopher, Ogden Leanne, Nair Beena
机构信息
Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
Department of Histopathology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
出版信息
BMJ Case Rep. 2017 Nov 12;2017:bcr-2016-218623. doi: 10.1136/bcr-2016-218623.
Abstract
Two patients developed kidney failure due to oxalate deposition in the kidney while taking orlistat. Cessation of orlistat was followed by partial recovery of kidney function. The mechanism by which orlistat causes hyperoxaluria and the management of orlistat-induced oxalate nephropathy is reviewed. We suggest that all patients taking orlistat are at risk of this condition, which may develop insidiously and is easily overlooked. Monitoring of kidney function of patients taking orlistat is warranted.
摘要
两名患者在服用奥利司他期间因草酸在肾脏沉积而出现肾衰竭。停用奥利司他后，肾功能部分恢复。本文综述了奥利司他导致高草酸尿症的机制以及奥利司他所致草酸肾病的治疗方法。我们认为，所有服用奥利司他的患者都有患此病的风险，该病可能隐匿发展且容易被忽视。对服用奥利司他的患者进行肾功能监测是必要的。
相似文献
1
Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.
BMJ Case Rep. 2017 Nov 12;2017:bcr-2016-218623. doi: 10.1136/bcr-2016-218623.
2
Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.
Diabetes Metab. 2016 Feb;42(1):62-4. doi: 10.1016/j.diabet.2015.08.006. Epub 2015 Oct 9.
3
An unusual complication of treatment with orlistat.
Clin Nephrol. 2009 Apr;71(4):430-2. doi: 10.5414/cnp71430.
4
When the Cause Is Not Crystal Clear.
N Engl J Med. 2020 Jan 2;382(1):74-78. doi: 10.1056/NEJMcps1809996.
5
Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis?
Nephrol Dial Transplant. 2008 May;23(5):1778-9. doi: 10.1093/ndt/gfm945. Epub 2008 Feb 13.
6
Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria.
Nephrology (Carlton). 2013 Mar;18(3):241-2. doi: 10.1111/j.1440-1797.2012.01649.x.
7
Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.
J La State Med Soc. 2013 Sep-Oct;165(5):283-5.
8
Orlistat and calcium oxalate crystalluria: an association that needs consideration.
Ren Fail. 2010;32(8):1019-21. doi: 10.3109/0886022X.2010.501929.
9
Orlistat, an under-recognised cause of progressive renal impairment.
Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv172-4. doi: 10.1093/ndt/gft066. Epub 2013 Sep 18.
10
Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.
Am J Kidney Dis. 2007 Jan;49(1):153-7. doi: 10.1053/j.ajkd.2006.10.004.
引用本文的文献
1
Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.
Heliyon. 2024 Jul 18;10(14):e34837. doi: 10.1016/j.heliyon.2024.e34837. eCollection 2024 Jul 30.
2
Assessment and management of chronic kidney disease in people living with obesity.
Clin Med (Lond). 2023 Jul;23(4):353-356. doi: 10.7861/clinmed.2023-0195.
3
Current and emerging medications for the management of obesity in adults.
Med J Aust. 2023 Apr 3;218(6):276-283. doi: 10.5694/mja2.51871. Epub 2023 Mar 19.
4
Oxalate crystal-related acute renal injury caused by orlistat: A case report.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 May 28;47(5):583-587. doi: 10.11817/j.issn.1672-7347.2022.210393.
5
Case - Orlistat-induced calcium oxalate crystalluria.
Can Urol Assoc J. 2022 Oct;16(10):371-373. doi: 10.5489/cuaj.7900.
6
Management of Obesity in Adults with CKD.
J Am Soc Nephrol. 2021 Apr;32(4):777-790. doi: 10.1681/ASN.2020101472. Epub 2021 Feb 18.
7
Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?
Front Endocrinol (Lausanne). 2020 Aug 17;11:289. doi: 10.3389/fendo.2020.00289. eCollection 2020.
8
Calcium oxalate crystal deposition in the kidney: identification, causes and consequences.
Urolithiasis. 2020 Oct;48(5):377-384. doi: 10.1007/s00240-020-01202-w. Epub 2020 Jul 27.
9
Secondary Oxalate Nephropathy: A Systematic Review.
Kidney Int Rep. 2018 Jul 29;3(6):1363-1372. doi: 10.1016/j.ekir.2018.07.020. eCollection 2018 Nov.
10
Medical therapy for nephrolithiasis: State of the art.
Asian J Urol. 2018 Oct;5(4):243-255. doi: 10.1016/j.ajur.2018.08.005. Epub 2018 Sep 3.
本文引用的文献
1
AJKD Atlas of Renal Pathology: Oxalosis.
Am J Kidney Dis. 2017 Mar;69(3):e13-e14. doi: 10.1053/j.ajkd.2017.01.006.
2
Acute oxalate nephropathy associated with orlistat.
J Nephropathol. 2016 Apr;5(2):79-83. doi: 10.15171/jnp.2016.14. Epub 2016 Mar 29.
3
The management of patients with enteric hyperoxaluria.
Urolithiasis. 2016 Feb;44(1):33-43. doi: 10.1007/s00240-015-0846-5. Epub 2015 Dec 8.
4
Enteric hyperoxaluria: an important cause of end-stage kidney disease.
Nephrol Dial Transplant. 2016 Mar;31(3):375-82. doi: 10.1093/ndt/gfv005. Epub 2015 Feb 20.
5
Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis.
Transl Androl Urol. 2014 Sep 1;3(3):256-276. doi: 10.3978/j.issn.2223-4683.2014.06.04.
6
Acute oxalate nephropathy associated with orlistat: a case report with a review of the literature.
Case Rep Nephrol. 2013;2013:124604. doi: 10.1155/2013/124604. Epub 2013 May 8.
7
Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.
J La State Med Soc. 2013 Sep-Oct;165(5):283-5.
8
Obesity in CKD--what should nephrologists know?
J Am Soc Nephrol. 2013 Nov;24(11):1727-36. doi: 10.1681/ASN.2013040330. Epub 2013 Oct 10.
9
Orlistat, an under-recognised cause of progressive renal impairment.
Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv172-4. doi: 10.1093/ndt/gft066. Epub 2013 Sep 18.
10
NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.
Kidney Int. 2013 Nov;84(5):895-901. doi: 10.1038/ki.2013.207. Epub 2013 Jun 5.
Zotero 插件